Vector BioPharma AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vector BioPharma AG - overview
Established
2021
Location
Basel, -, Switzerland
Primary Industry
Biotechnology
About
Based in Basel, Switzerland, and founded in 2021 by its CEO, Lorenz Mayr, and Andreas Plückthun, Vector BioPharma AG, operates as a biopharmaceutical company that offers platform technologies for genetic medicine. In August 2022, Vector BioPharma AG raised USD 30 million in series A funding from investor Versant Ventures. The company offers a proprietary platform that helps to transform the safety, efficacy, and specificity of tissue-specific delivery and tunable expression of genes and regulators. The company uses capsid shielding technology to help develop genetic medicine and treat important diseases.
The company plans to use the August 2022 funding to support its new gene therapy vector, as well as hire staff and expand its platform.
Current Investors
Versant Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.vectorbiopharma.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.